Personalized Bacteriophage Therapy Against Pandrug-Resistant Spinal Pseudomonas Aeruginosa Infection

Visualization of Plaque Forming Units (PFU) of the different phages on the patient’s strains isolated before phage therapy or during the second-stage surgery procedure.

Bone and joint infections (BJI) are one of the most difficult-to-treat bacterial infection, especially in the era of antimicrobial resistance.

Lytic bacteriophages are natural viruses that can selectively target and kill bacteria. They are considered to have a high therapeutic potential for the treatment of severe bacterial infections and especially BJI, as they also target biofilms.

Tristan et al. have reported on the management of a patient with a pandrug-resistant Pseudomonas aeruginosa spinal abscess who was treated with surgery and a personalized combination of phage therapy that was added to antibiotics. As the infecting P. aeruginosa strain was resistant to the phages developed by private companies that were contacted, they set up a unique European academic collaboration to find, produce and administer a personalized phage cocktail to the patient in due time.

After two surgeries, despite bacterial persistence with expression of small colony variants, the patient healed with local and intravenous injections of purified phages as adjuvant therapy.


Dr. Ferry Tristan will be joining  Targeting Phage Therapy 2023 to further explain about this personalized bacteriophage therapy.

Register for Targeting Phage and Antibiotic Resistance 2023.

Targeting Phage Therapy 2023 Congress
6th World Conference
June 1-2, 2023